No Data
No Data
No Data
No Data
No Data
Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Yahoo FinanceMay 3 20:41
Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating
SpringWorks Therapeutics (SWTX) has an average rating of buy and price targets ranging from $58 to $80, according to analysts polled by Capital IQ. Price: 43.54, Change: -3.30, Percent Change: -7.05
MT NewswiresMay 3 00:25
SpringWorks Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 EPS Results.
SpringWorks Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 EPS Results.
BenzingaMay 2 22:52
Buy Rating for Springworks Therapeutics Amid Strong Market Performance and Promising Pipeline
TipRanksMay 2 21:37
SpringWorks Therapeutics Cash, Cash Equivalents and Marketable Securities Were $573M as of March 31 >SWTX
SpringWorks Therapeutics Cash, Cash Equivalents and Marketable Securities Were $573M as of March 31 >SWTX
Dow JonesMay 2 18:33
SpringWorks Therapeutics Q1 2024 GAAP EPS $(1.18) Misses $(1.16) Estimate, Sales $21.006M Beat $12.206M Estimate
SpringWorks Therapeutics (NASDAQ:SWTX) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.16) by 1.72 percent. This is unchanged from the same period las
BenzingaMay 2 18:32
No Data
No Data